Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Completed1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT01259817Phase 2Completed
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera
Principalinvestigator

Research Network

Collaboration Network

21 collaborators·21 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Myeloproliferative Disorders-Research Consortium

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

7 similar investigators found

Jean-Jacques Kiladjian, MD

Hopitaux de Paris

Moderately Similar
1 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Similarity Score30%

Mary Frances McMullin, MD

Belfast Health and Social Care Trust

Moderately Similar
1 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Similarity Score30%

Ronald Hoffman, MD

Icahn School of Medicine at Mount Sinai

Moderately Similar
10 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Similarity Score30%

Claire Harrison, MD

Guy's and St Thomas' NHS Foundation Trust

Moderately Similar
1 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Similarity Score30%

Ruben Mesa, MD

Mayo Clinic

Moderately Similar
2 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Similarity Score30%

Ellen Ritchie, MD

Myeloproliferative Disorders-Research Consortium

Related
1 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Collaborated on 1 trial
Similarity Score24%

John Mascarenhas, MD

Icahn School of Medicine at Mount Sinai

Related
16 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Collaborated on 1 trial
Similarity Score24%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT01259817Phase 2PrincipalInvestigator

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera
Completed

All 1 trials loaded